{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:05:01Z","timestamp":1791050701478,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2020,7,14]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Adaptive immune resistance mediated by the cytokine interferon gamma (IFNG) still constitutes a major problem in cancer immunotherapy. We develop strategies for overcoming IFNG-mediated adaptive immune resistance in pancreatic ductal adenocarcinoma cancer (PDAC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>We screened 429 kinase inhibitors for blocking IFNG-induced immune checkpoint (indoleamine 2,3-dioxygenase 1 (IDO1) and CD274) expression in a human PDAC cell line. We evaluated the ability of the cyclin-dependent kinase (CDK) inhibitor dinaciclib to block IFNG-induced <jats:italic>IDO1<\/jats:italic> and <jats:italic>CD274<\/jats:italic> expression in 24 human and mouse cancer cell lines as well as in primary cancer cells from patients with PDAC or ovarian carcinoma. We tested the effects of dinaciclib on IFNG-induced signal transducer and activator of transcription 1 activation and immunological cell death, and investigated the potential utility of dinaciclib in combination with IFNG for pancreatic cancer therapy in vivo, and compared gene expression levels between human cancer tissues with patient survival times using the Cancer Genome Atlas datasets.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pharmacological (using dinaciclib) or genetic (using shRNA or siRNA) inactivation of CDK1\/2\/5 not only blocks JUN-dependent immune checkpoint expression, but also triggers histone-dependent immunogenic cell death in immortalised or primary cancer cells in response to IFNG. This dual mechanism turns an immunologically \u2018cold\u2019 tumour microenvironment into a \u2018hot\u2019 one, dramatically improving overall survival rates in mouse pancreatic tumour models (subcutaneous, orthotopic and transgenic models). The abnormal expression of CDK1\/2\/5 and IDO1 was associated with poor patient survival in several cancer types, including PDAC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CDK1\/2\/5 kinase activity is essential for IFNG-mediated cancer immunoevasion. CDK1\/2\/5 inhibition by dinaciclib provides a novel strategy to overcome IFNG-triggered acquired resistance in pancreatic tumour immunity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2019-320441","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T17:22:02Z","timestamp":1597425722000},"page":"890-899","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":104,"title":["CDK1\/2\/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer"],"prefix":"10.1136","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct02077881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02077881","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jin","family":"Huang","sequence":"first","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"},{"name":"Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Cancer Hospital, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Liu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borong","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runliu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Peng","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-0610","authenticated-orcid":false,"given":"Ze-Xian","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Endoscopy Center, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[{"name":"Equipe Labellis\u00e9e Par la Ligue Contre le Cancer, Universit\u00e9 Paris Descartes, Paris, \u00cele-de-France, France"},{"name":"Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"P\u00f4le de Biologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France"},{"name":"Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China"},{"name":"Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lotze","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Zeh","sequence":"additional","affiliation":[{"name":"Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-6180","authenticated-orcid":false,"given":"Daolin","family":"Tang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"},{"name":"Department of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"2025090714355743000_70.5.890.1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J Immunol"},{"key":"2025090714355743000_70.5.890.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025090714355743000_70.5.890.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2025090714355743000_70.5.890.4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031435","article-title":"Kras: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025090714355743000_70.5.890.5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337"},{"key":"2025090714355743000_70.5.890.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0164-5"},{"key":"2025090714355743000_70.5.890.7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431086","article-title":"Tfam is a novel mediator of immunogenic cancer cell death","volume":"7","author":"Yang","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025090714355743000_70.5.890.8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.celrep.2019.03.037","article-title":"Autophagy Regulation of Metabolism Is Required for CD8+ T Cell Anti-tumor Immunity","volume":"27","author":"DeVorkin","year":"2019","journal-title":"Cell Rep"},{"key":"2025090714355743000_70.5.890.9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2017.12.004","article-title":"JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice","volume":"154","author":"Song","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090714355743000_70.5.890.10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2017.07.036","article-title":"Inhibition of Aurora Kinase A Induces Necroptosis in\u00a0Pancreatic\u00a0Carcinoma","volume":"153","author":"Xie","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090714355743000_70.5.890.11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/cr.2017.51","article-title":"Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer","volume":"27","author":"Kang","year":"2017","journal-title":"Cell Res"},{"key":"2025090714355743000_70.5.890.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0215"},{"key":"2025090714355743000_70.5.890.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01044","article-title":"Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment","volume":"9","author":"Foucher","year":"2018","journal-title":"Front Immunol"},{"key":"2025090714355743000_70.5.890.14","doi-asserted-by":"publisher","DOI":"10.1021\/ml100051d"},{"key":"2025090714355743000_70.5.890.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019468"},{"key":"2025090714355743000_70.5.890.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.138"},{"key":"2025090714355743000_70.5.890.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"2025090714355743000_70.5.890.18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI94586","article-title":"Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression","volume":"128","author":"Hossain","year":"2018","journal-title":"J Clin Invest"},{"key":"2025090714355743000_70.5.890.19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JP9.0000000000000002","article-title":"The dual role of HMGB1 in pancreatic cancer","volume":"1","author":"Kang","year":"2018","journal-title":"Journal of Pancreatology"},{"key":"2025090714355743000_70.5.890.20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4103\/0366-6999.201613","article-title":"Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer","volume":"130","author":"Zhang","year":"2017","journal-title":"Chin Med J"},{"key":"2025090714355743000_70.5.890.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature25015"},{"key":"2025090714355743000_70.5.890.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0477"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-320441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:36:04Z","timestamp":1757280964000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-320441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,7]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/gutjnl-2019-320441"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-320441","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}